Skip to main content

BioNexus Gene Lab Corp

corporate_fare Company Profile

BioNexus Gene Lab Corp

BGLC·NASDAQ·Industrial Applications And Services·CIK 0001737523

BioNexus Gene Lab Corp. is a Wyoming corporation operating through two main subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. and MRNA Scientific Sdn. Bhd. Chemrex distributes chemical raw materials primarily for industrial applications across Southeast Asia, serving the industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in countries including Malaysia, Indonesia, and Vietnam. MRNA Scientific develops and provides blood-based genomic screening services for early disease risk assessment and health management. In November 2025, the company expanded its focus in molecular diagnostics and oncology-related screening technologies by entering into a Share Subscription and Shareholders' Agreement with Fidelion Diagnostics Pte. Ltd. and related parties. Concurrently, it secured an exclusive, perpetual license for the VitaGuard™ Minimal Residual Disease (MRD) platform in the ASEAN region. The company's principal executive office is located in Kuala Lumpur, Malaysia.

BioNexus Gene Lab Corp (NASDAQ:BGLC) is a publicly traded company in the Industrial Applications And Services sector. Wiseek monitors BGLC SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • BioNexus Gene Lab Corp's Q1 Revenue Crashes 99% to $22.84K, Deepening Going Concern Worries
  • BioNexus Gene Lab Reports 98.9% Revenue Collapse, Ongoing Going Concern Doubt, and Sues Former Officers for $2.9M
  • Annual Report Reveals Going Concern Doubt, Material Weakness, and Significant Dilution Risks
  • BioNexus Gene Lab Corp.'s Strategic Partner Fidelion Diagnostics Appoints Dr. Muthu Meyyappan as Chief Commercial Officer
  • BioNexus Gene Lab Completes Subsidiary Governance Restructuring, Appoints New Chairman

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$7.42M
Net Income
-$2.98M
Op. Cash Flow
-$1.84M
Free Cash Flow
-$1.88M
Gross Profit
$1.09M
Operating Income
-$2.97M
Cash & Equivalents
$2.49M
Debt / Equity
0.00×
Net Margin
-40.2%
Shares Outstanding
2.42M sh
Source: 10-K · filed 2026-04-14 · accession 0001477932-26-002218
Browse all tickers starting with B →
$2.02 -0.12% today
52-week range · as of 2026-05-15 $1.92 – $15.6
Market cap
$5.17M
Volume
160.2K (0.8× avg)
3-mo avg 190.6K
Live data · 2026-06-14 03:52 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed BGLC - Latest Insights

BGLC
May 15, 2026, 5:21 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $2.02
Real-time Price: $2.02 info
Change: +$0.000863 (+0.04%) info
Market Cap: $5.173M info
BGLC
May 15, 2026, 5:15 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $2.02
Real-time Price: $2.02 info
Change: +$0.000863 (+0.04%) info
Market Cap: $5.173M info
BGLC
Apr 14, 2026, 5:20 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $2.17
Real-time Price: $2.02 info
Change: -$0.150 (-7%) info
Market Cap: $5.173M info
BGLC
Mar 17, 2026, 2:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.54
Real-time Price: $2.02 info
Change: -$0.520 (-20%) info
Market Cap: $5.173M info
BGLC
Feb 23, 2026, 8:35 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.43
Real-time Price: $2.02 info
Change: -$0.410 (-17%) info
Market Cap: $5.173M info
BGLC
Feb 03, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.65
Real-time Price: $2.02 info
Change: -$0.630 (-24%) info
Market Cap: $5.173M info